nancy williams, a 70-year-old markham, ontario woman, says she wasn’t aware of rsv when she experienced symptoms a year ago that left her out of commission and in bed for two weeks, and then slowly feeling more like herself over the next several weeks.
“i get colds every year, but this was different. this was headaches and wheezing and shortness of breath, along with runny nose, like crazy, but mostly the respiratory symptoms were the worst,” she says. “whenever you have shortness of breath, it’s very scary.” williams lives alone and has adult children who are in the greater toronto area, but she doesn’t like to impose.
she took multiple covid-19 rapid tests, but all were negative. while never officially diagnosed with rsv, her pharmacists told her that’s likely what she had.
“it took me a long time to just feel normal again,” williams says, adding she had pneumonia two years ago and was referred to a respirologist for monitoring. “i have to be careful, especially at this age. i don’t have diabetes or anything serious, but i do think my lungs make me more susceptible [to viruses].”
she’s already had her flu and covid vaccines and plans to get the rsv vaccine as well.
earlier this week, gsk’s arexvy was approved by the regulator for adults 50 to 59 years of age who are at increased risk for rsv disease. the vaccine previously was approved for adults aged 60 and older and is strongly recommended by the national advisory committee on immunization for all adults 75 years and older and those aged 60 and above in nursing homes and other chronic care facilities. the committee also recommends that adults aged 60 to 74 years may consider rsv vaccination in consultation with a healthcare provider.